Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...

Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Claseprubart granted ...

The first quarter 2026 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be ...

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people ...

Investigational treatment improves outcomes without complete complement blockade ...

In a double-blind, placebo-controlled phase 2 randomized clinical trial, vemircopan did not meet the predefined efficacy ...

What was once viewed as experimental is now entering a phase of operational maturity. The Turing Award recognition ...

Proof-of-Concept (POC) Data for ANX1502, a First-in-Kind Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026 ...

The IMpactMF trial’s interim analysis in the second half of 2026 is presented as a potential catalyst with implications for both product expansion and physician awareness. Expectations for back-half ...

Argenx Brings Neuromuscular Leadership To AAN 2026 With New Data Supporting Broader VYVGART Use Across MG And CIDP. <li /> ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular ...

IIIT Dharwad’s CoE aims to bring quantum access, training, and industry links to tier-2 regions within months.

Two twins grow up in the same household, eat the same meals, attend the same schools, and share the same parents. By age 27, ...